Advisors

James worked across a number of industries including several of the big five pharmaceutical enterprises where he was lead engagement Partner. James was also responsible for the travel, transportation and services industry across the Deloitte UK organisation.

James was a member of the Deloitte Partnership committee for 10 years responsible for the vetting of all Partner recruits across the UK business and assessing readiness of all new Partner promotion and Partner to equity Partner candidates. He is currently a Non Executive Director and Board Advisor and helps Deka with key industry contacts and assessing current sector trends.

He has established and run talent solutions and staffing businesses in North America, the UK, Middle East and Africa. He was interim CIO, drove digital and organisational transformation programmes and owned, and executed on the Group’s innovation strategy. Since leaving Page, Olly has taken a number of Non Executive and Advisory positions in the recruitment, engineering and technology sectors

He advised across a variety of sectors, but for the last 12 years at KPMG he led KPMG UK’s Private Sector Healthcare and mid-market Life Sciences practice across all service lines.

Roger advised on over 100 transactions in the Health & Life Science sector, in the UK, USA, Germany, France, Australia, Egypt. Clients ranged from early stage biotechs to large national and international healthcare and pharma businesses, Private Equity and banks. Deal size £10m-£1bn.

Subsectors include aged care, hospital based care, mental health, children’s care & education, diagnostics, imaging, pharmaceuticals, pharmacy, biotech, pharma services, animal health, health technology. Transaction types include acquisitions, disposals, IPOs, refinancing.

Roger served for over 10 years on KPMG’s Global Healthcare Steering Committee, which drives strategy and growth across the firm’s international healthcare practice of 45 countries. He managed and co-ordinated both domestic and cross-border Deal Advisory strategy and collaboration. This role provided valuable insight into healthcare systems in a wide variety of geographies including the UK, USA, most of Western Europe, parts of Asia and Africa, and the Middle East.

He joined CIL in 1996, became Partner in 2003 and head of Healthcare in 2005. He ran the practice until he stepped back to senior advisor and non-executive director in 2022.

He was also Managing Partner 2019-22.
He has led numerous engagements across a range of life sciences, health tech, products and services markets. Giles has particular experience conducting sell- and buy-side commercial due diligence for private equity investors in the sector such as GHO, Apposite Capital, Archimed, Elysian Capital and CBPE.